BioNTech SE ( ($BNTX) ) has shared an update. On April 4, 2025, BioNTech SE announced the invitation to its Annual General Meeting scheduled for ...

Several pharma CEOs met with Chinese President Xi Jinping in Beijing. President Donald Trump's reciprocal tariffs have mostly ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

We recently published a list of 12 Best German Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

Mitsubishi UFJ Asset Management Co. Ltd. reduced its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 20.0% in the 4th ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $145 from $150 and keeps a Buy rating on the shares. The firm says ...

Organizations that develop sophisticated approaches to IP risk management can protect their exit potential and create ...

The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

CureVac N.V. secured funding with GSK amid financial struggles, while a key patent win boosts stock. Click for why my ...